Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling.

Misregulated interleukin-6 (IL-6)-induced Jak/STAT signaling contributes to many diseases. Under non-pathological conditions Jak/STAT signaling is tightly regulated by a complex network of regulators. One of these regulators is the protein tyrosine phosphatase SH2-containing phosphatase 2 (SHP2). Although SHP2 is known to be a negative regulator of IL-6-induced Jak/STAT signaling, its exact molecular function is not entirely understood. To elucidate the function of SHP2 in IL-6 signaling we followed a systems biology approach, in which modeling, stepwise model refinement, and experimental analysis are closely linked. We come up with an identifiable model of early Jak/STAT signaling that describes the data and proves to be predictive. The model-based analysis implies that (1) the stepwise association of IL-6 with gp80 and gp130 and (2) STAT3 dimerization at the receptor are essential for the dynamics of early pathway activation, and (3) phosphorylation of SHP2 is nonlinear. Furthermore, the modeling results indicate that SHP2 does not act as a feedback inhibitor in an early phase of IL-6-induced Jak/STAT signaling. However, experimental data reveal that SHP2 exhibits a basal repressory function.

[1]  Dipak Barua,et al.  Structure-based kinetic models of modular signaling protein function: focus on Shp2. , 2007, Biophysical journal.

[2]  A. Jayaraman,et al.  Modeling regulatory mechanisms in IL‐6 signal transduction in hepatocytes , 2006, Biotechnology and bioengineering.

[3]  T. Hirano,et al.  IL-6 signal transduction and its physiological roles: the signal orchestration model. , 2003, Reviews of physiology, biochemistry and pharmacology.

[4]  D. Barford,et al.  Revealing mechanisms for SH2 domain mediated regulation of the protein tyrosine phosphatase SHP-2. , 1998, Structure.

[5]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[6]  Holger Conzelmann,et al.  Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. , 2011, Molecular cell.

[7]  Satoru Shiono,et al.  Control mechanism of JAK/STAT signal transduction pathway , 2003, FEBS letters.

[8]  G. Yancopoulos,et al.  The protein tyrosine phosphatase SHP-2 negatively regulates ciliary neurotrophic factor induction of gene expression , 1997, Current Biology.

[9]  P. Heinrich,et al.  The Cytoplasmic Tyrosine Motifs in Full-Length Glycoprotein 130 Have Different Roles in IL-6 Signal Transduction1 , 2000, The Journal of Immunology.

[10]  I. Kerr,et al.  Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. , 1998, The Biochemical journal.

[11]  S. Harrison,et al.  Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 , 1996, Nature.

[12]  Wei Lu,et al.  Site-specific incorporation of a phosphotyrosine mimetic reveals a role for tyrosine phosphorylation of SHP-2 in cell signaling. , 2001, Molecular cell.

[13]  P. Heinrich,et al.  Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level , 1993, Molecular and cellular biology.

[14]  P. Heinrich,et al.  Cytoplasmic STAT proteins associate prior to activation. , 2000, The Biochemical journal.

[15]  Tetsuya Yamamoto,et al.  The nuclear isoform of protein-tyrosine phosphatase TC-PTP regulates interleukin-6-mediated signaling pathway through STAT3 dephosphorylation. , 2002, Biochemical and biophysical research communications.

[16]  Sebastian Bohl,et al.  Theoretical Analysis of Time-to-Peak Responses in Biological Reaction Networks , 2011, Bulletin of mathematical biology.

[17]  J. Johnston,et al.  The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. , 2004, The Biochemical journal.

[18]  J. Darnell,et al.  Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors , 1995, Science.

[19]  Martin Mönnigmann,et al.  A simple work flow for biologically inspired model reduction - application to early JAK-STAT signaling , 2011, BMC Systems Biology.

[20]  G. Müller-Newen,et al.  The role of the N-terminal domain in dimerization and nucleocytoplasmic shuttling of latent STAT3 , 2009, Journal of Cell Science.

[21]  Martin Mönnigmann,et al.  Systematic identifiability testing for unambiguous mechanistic modeling – application to JAK-STAT, MAP kinase, and NF-κB signaling pathway models , 2009, BMC Systems Biology.

[22]  Jens Schneider-Mergener,et al.  SHP2 and SOCS3 Contribute to Tyr-759-dependent Attenuation of Interleukin-6 Signaling through gp130* , 2003, The Journal of Biological Chemistry.

[23]  T. Hirano,et al.  IL-6 in autoimmune disease and chronic inflammatory proliferative disease. , 2002, Cytokine & growth factor reviews.

[24]  C. Schindler,et al.  STATs Dimerize in the Absence of Phosphorylation* , 2003, Journal of Biological Chemistry.

[25]  J. Darnell,et al.  Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. , 1994, Science.

[26]  Stefan Rose-John,et al.  Dynamics of the gp130 cytokine complex: A model for assembly on the cellular membrane , 2005, Protein science : a publication of the Protein Society.

[27]  M. Tremblay,et al.  Protein Tyrosine Phosphatases, TC-PTP, SHP1, and SHP2, Cooperate in Rapid Dephosphorylation of Stat3 in Keratinocytes Following UVB Irradiation , 2010, PLoS ONE.

[28]  G. Gores,et al.  Sorafenib inhibits signal transducer and activator of transcription‐3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 , 2009, Hepatology.

[29]  G. Yancopoulos,et al.  Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. , 1994, Science.

[30]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[31]  T. Han,et al.  Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. , 2011, Cancer cell.

[32]  C. Schindler,et al.  Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. , 1994, Science.

[33]  P. Cole,et al.  Chemical dissection of the effects of tyrosine phosphorylation of SHP-2. , 2003, Biochemistry.

[34]  H. Baumann,et al.  Protein Tyrosine Phosphatase 2 (SHP-2) Moderates Signaling by gp130 but Is Not Required for the Induction of Acute-Phase Plasma Protein Genes in Hepatic Cells , 1998, Molecular and Cellular Biology.

[35]  J Timmer,et al.  Quantitative data generation for systems biology: the impact of randomisation, calibrators and normalisers. , 2005, Systems biology.

[36]  S. Shoelson,et al.  Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.

[37]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[38]  Xin-Yuan Fu,et al.  Negative Regulation of Stat3 by Activating PTPN11 Mutants Contributes to the Pathogenesis of Noonan Syndrome and Juvenile Myelomonocytic Leukemia* , 2009, The Journal of Biological Chemistry.

[39]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.